Silence Therapeutics PLC (SLN) Stock AnalysisSLNStock AnalysisSilence Therapeutics PLC

Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Silence Therapeutics PLC is a good buy right now due to its recent positive catalysts, including a successful Phase 2 trial for Divesiran, which showed an 88% response rate in treated patients. The current price of $13.42 is significantly lower than the analyst price target of $32 from Morgan Stanley, indicating a potential upside of 138%. Additionally, the stock has experienced a year-to-date change of +118.21%, reflecting strong momentum. However, investors should be cautious of the company's high net losses, which reached -$12.68 million in Q2 2026, posing a risk to financial stability.